Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 419.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,075 shares of the biopharmaceutical company's stock after buying an additional 46,886 shares during the period. Tower Research Capital LLC TRC's holdings in Amicus Therapeutics were worth $547,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. MetLife Investment Management LLC boosted its position in Amicus Therapeutics by 5.9% in the 4th quarter. MetLife Investment Management LLC now owns 179,555 shares of the biopharmaceutical company's stock valued at $1,691,000 after buying an additional 10,056 shares during the period. Mesirow Institutional Investment Management Inc. raised its stake in shares of Amicus Therapeutics by 9.3% during the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 89,382 shares of the biopharmaceutical company's stock valued at $842,000 after acquiring an additional 7,630 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Amicus Therapeutics by 7.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 80,076 shares of the biopharmaceutical company's stock valued at $753,000 after purchasing an additional 5,522 shares during the period. Farringdon Capital Ltd. bought a new position in Amicus Therapeutics in the fourth quarter worth approximately $107,000. Finally, Marshall Wace LLP increased its holdings in Amicus Therapeutics by 254.2% during the 4th quarter. Marshall Wace LLP now owns 72,968 shares of the biopharmaceutical company's stock worth $687,000 after purchasing an additional 52,368 shares during the period.

Amicus Therapeutics Stock Down 0.1 %

Shares of FOLD stock traded down $0.01 during trading hours on Friday, reaching $6.67. 6,371,892 shares of the company's stock were exchanged, compared to its average volume of 2,692,364. Amicus Therapeutics, Inc. has a fifty-two week low of $6.20 and a fifty-two week high of $12.65. The stock's 50 day moving average is $7.95 and its 200-day moving average is $9.27. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -37.06, a P/E/G ratio of 1.51 and a beta of 0.79.

Wall Street Analyst Weigh In

FOLD has been the subject of several research reports. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. The Goldman Sachs Group cut their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday. UBS Group upped their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.